Genome-Wide Association Study of Human Immunodeficiency Virus (HIV)-1 Coreceptor Usage in Treatment-Naive Patients from An AIDS Clinical Trials Group Study by Henrich, T.J. et al.
M A J O R A R T I C L E
Genome-Wide Association Study of Human
Immunodeﬁciency Virus (HIV)-1 Coreceptor
Usage in Treatment-Naive Patients from An
AIDS Clinical Trials Group Study
Timothy J. Henrich,1,2 Paul J. McLaren,3,4,5 Suhas S. P. Rao,6 Nina H. Lin,7,2 Emily Hanhauser,1 Francoise Giguel,7
Roy M. Gulick,8 Heather Ribaudo,2,9 Paul I. W. de Bakker,2,10,11,12 and Daniel R. Kuritzkes1,2
1Division of Infectious Diseases, Brigham and Women’s Hospital, Boston, Massachusetts; 2Harvard Medical School, Boston, Massachusetts; 3École
Polytechnique Fédérale de Lausanne and University of Lausanne, Switzerland; 4University Hospital and University of Lausanne, Switzerland; 5Swiss
Institute of Bioinformatics, Switzerland; 6Harvard University, Cambridge, Massachusetts; 7Massachusetts General Hospital, Boston, Massachusetts;
8Weill Medical College of Cornell University, New York, New York; 9Harvard School of Public Health; 10Program in Medical and Population Genetics, Broad
Institute of Harvard and MIT, Boston, Massachusetts; 11Department of Medical Genetics and Department of Epidemiology, University Medical Center
Utrecht, Utrecht, The Netherlands; and 12Divison of Genetics, Brigham and Women’s Hospital, Boston, Massachusetts
Objectives. We conducted a genome-wide association study to explore whether common host genetic variants
(>5% frequency) were associated with presence of virus able to use CXCR4 for entry.
Methods. Phenotypic determination of human immunodeﬁciency virus (HIV)-1 coreceptor usage was performed
on pretreatment plasma HIV-1 samples from treatment-naive participants in AIDS Clinical Trials Group A5095, a study
of initial antiretroviral regimens. Associations between genome-wide single-nucleotide polymorphisms (SNPs), CCR5
Δ32 genotype, and human leukocyte antigen (HLA) class I alleles and viral coreceptor usage were explored.
Results. Viral phenotypes were obtained from 593 patients with available genome-wide SNP data. Forty-four per-
cent of subjects had virus capable of using CXCR4 for entry as determined by phenotyping. Overall, no associations,
including those between polymorphisms in genes encoding viral coreceptors and their promoter regions or in HLA
genes previously associated with HIV-1 disease progression, passed the statistical threshold for genome-wide signiﬁcance
(P < 5.0 × 10−8) in any comparison. However, the presence of viruses able to use CXCR4 for entry was marginally as-
sociated with the CCR5 Δ32 genotype in the nongenome-wide analysis.
Conclusions. No human genetic variants were signiﬁcantly associated with virus able to use CXCR4 for entry at the
genome-wide level. Although the sample size had limited power to deﬁnitively exclude genetic associations, these results
suggest that host genetic factors, including those that inﬂuence coreceptor expression or the immune pressures leading
to viral envelope diversity, are either rare or have only modest effects in determining HIV-1 coreceptor usage.
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Human immunodeﬁciency virus (HIV)-1 that uses CCR5
exclusively for entry into host cells (R5 virus) is primarily
responsible for viral transmission and predominates in
early infection. Human immunodeﬁciency virus-1 that
uses CXCR4, either exclusively (X4 virus) or both CXCR4
and CCR5 (dual- or mixed-tropic virus populations
[D/M]), emerges in patients over time. The shift in cor-
eceptor usage has clinical implications because X4 emer-
gence correlates with accelerated CD4 count decline and
progression to acquired immune deﬁciency syndrome
(AIDS) [1–8]. A better understanding of the relationship
between the evolution of coreceptor usage and variations
in host genetics is important because modulating CCR5
expression or function is being studied as a strategy to
achieve antiretroviral-free HIV-1 remission [9–12].
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Coreceptor switching and X4-D/M emergence may occur
due to changes in target cell availability, replication differences
among R5 and X4 variants in various immune cells, or differ-
ences in host immune responses to R5 and X4 viruses [8, 13–
17]. However, there is little understanding about speciﬁc host
factors that facilitate emergence of CXCR4-using viral variants.
Common host genetic polymorphisms (frequency >5%) have
been identiﬁed in HIV-1 coreceptor or coreceptor ligand
genes that modify the rate of disease progression or susceptibil-
ity to infection [7, 18–24], but data to support the role of host
factors involved in coreceptor usage switching are limited. As a
result, we conducted a genome-wide association study (GWAS)
to explore whether common host genetic variants are associated
with the presence of X4-D/M virus in a cross-sectional study of
treatment-naive patients enrolled in AIDS Clinical Trials Group
(ACTG) protocol A5095 and explored the relationship between
CCR5 Δ32 mutations, demographic and clinical factors, and
viral coreceptor usage.
METHODS
Pretreatment, baseline plasma samples were obtained from pa-
tients enrolled in ACTG A5095, a 1147-patient randomized,
double-blind trial of a triple-nucleoside regimen versus efavir-
enz-containing regimens for the initial treatment of HIV-1 in-
fection, and coenrolled in A5128, a study to use stored human
biological materials for genetic analyses [21, 25, 26]. When in-
sufﬁcient sample was available, plasma obtained 2 or 4 weeks
after antiretroviral therapy (ART) initiation was used. The Part-
ners Healthcare institutional review board approved this study.
Virus was concentrated by centrifuging 500 µL plasma at
17 000× g for 1.5 h at 4°C before RNA extraction using the
QIAamp Viral RNA Mini Kit (QIAGEN). After RNA extrac-
tion, full-length envelope genes were ampliﬁed using nested po-
lymerase chain reaction with primers as described [27–29].
Polymerase chain reactions were performed in triplicate wells
and combined before further processing. Bidirectional sequenc-
ing of the third variable loop (V3) of HIV-1 envelope was per-
formed to check for potential sample cross-contamination and
to perform Geno2Pheno coreceptor usage prediction using a
5% false-positive rate threshold [30, 31].An in-house phenotyp-
ic assay able to detect minority X4 or D/M virus present at 1%
or greater of the virus population using pseudoviruses incorpo-
rating a luciferase reporter gene and full-length env amplicons
from population viral RNA was performed to determine core-
ceptor usage as described [32]. Phenotyping was repeated if the
luciferase signal on indicator cell lines was <20-fold higher than
the signal generated from envelope-deleted pseudovirus vectors
alone. The assay has been optimized for the categorical determi-
nation of coreceptor-usage results (eg, X4, X4-D/M, or R5).
Covariate-adjusted analyses using binary logistic regression
models were performed to identify associations between age,
gender, race or ethnicity, baseline CD4+ T-cell counts, baseline
log10 HIV RNA levels with viral coreceptor usage, and the pres-
ence of a CCR5 Δ32 mutation assessed by a custom Sequenom
iPLEX genotyping assay.
Genome-wide studies to identify associations between single-
nucleotide polymorphisms (SNPs) and viral coreceptor usage
were performed. We utilized >400 000 common SNPs geno-
typed using Illumina genome-wide genotyping arrays for asso-
ciation with HIV viral coreceptor usage (R5 virus and D/M or
X4 virus) for the study population as previously described [21].
In brief, samples were genotyped using the Illumina Human-
Hap650Y or 1MDuo platform. Quality control and data ﬁltering
were done using the PLINK toolset [33] based on population
outliers (judged by principal component analysis), signals of
contamination (large deviation from expected heterozygosity),
SNP missingness (missing in >5% of samples), low frequency
(minor alleles frequency below 1%), and the Hardy-Weinberg
equilibrium test (P < .000005).
Sample swaps were ruled out by using a ﬁngerprint panel of
<30 SNPs used for sample tracking. Known polymorphisms in
the CCR5 and CXCR4 genes not represented on the GWAS
chips were genotyped using a custom Sequenom iPLEX geno-
typing assay. Samples were split based on ancestry, and asso-
ciation testing was performed using logistic regression,
including markers for HIV disease stage that were identiﬁed
to be independently associated with coreceptor usage in addi-
tion to principal components calculated from genome-wide
SNP data to correct for residual population structure. Associ-
ation evidence was combined across groups using inverse-
variance weighted meta-analysis. Models were performed un-
adjusted or included baseline CD4+ T cell counts as a cofactor.
High-resolution major histocompatibility complex (MHC)
class I human leukocyte antigen (HLA) typing was available
for a majority of patients, and separate association analyses
were performed with viral coreceptor genotypes and
phenotypes.
RESULTS
Stored plasma samples from 751 participants in A5095 were ob-
tained from the ACTG specimen repository. Coreceptor usage
was determined by phenotypic assay for 593 patients with avail-
able SNP data. Table 1 shows the association between patient
demographic and clinical factors, including CCR5 genotype
with viral coreceptor usage. The X4-D/M virus was signiﬁcantly
associated with a lower baseline CD4+ T cell count (P < .001) in
the multivariate model and marginally, but not signiﬁcantly, as-
sociated with the presence of the CCR5 Δ32 allele (P = .058). Of
all X4-D/M viruses determined by phenotypic assay, only 0.9%
used CXCR4 exclusively.
A large majority of patients (94.2%) with available phenotyp-
ic coreceptor usage results had HIV-1 subtype B virus predicted
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by V3 loop genotype, and 46% of these patients had X4-D/M
virus by phenotypic assay. Subtype C and A (or AG)
represented 2.1% and 2.7% of patient viruses, respectively, but
only 23.1% and 17.6% of patients with these subtypes had X4-
D/M virus. Two patients each had D, G, and F subtypes with 1
subtype D patient having X4-D/M virus. Of samples with phe-
notypic coreceptor usage results, only 10 (1.7%) were obtained 2
or 4 weeks after ART initiation.
No associations between any SNPs and viral coreceptor
usage passed the genome-wide threshold for signiﬁcance
(P < 5 × 10−8) in any comparison. Table 2 shows the genome-
side association results for each ancestral population and a
meta-analysis across ancestral groups for disease-modifying
polymorphisms identiﬁed in CCR5, CCR2, and stromal cell-
derived factor 1 (SDF1)-3′A (A5095 consisted of participants
with European, African-American, and Mexican ethnicities).
Table 3 shows association results for disease-modifying poly-
morphisms adjusted for baseline CD4+ T-cell counts to mini-
mize potential disease stage bias, because CD4+ count was
strongly associated with the presence of X4-D/M virus in
non-GWAS regression modeling. The presence of CXCR4-
using virus was not signiﬁcantly associated with any of these
polymorphisms in either analysis, although presence of the
CCR5 Δ32 allele approached marginal nongenome-wide signif-
icance (P = .080) in the CD4+ T-cell count adjusted model.
Figure 1 shows Manhattan plots of all SNPs in the CD4+
T cell unadjusted analyses for each ancestral group and the
meta-analysis across ancestry; the 100 polymorphisms with
the lowest P values in the meta-analysis across ancestral associ-
ation data in the CD4+ T cell unadjusted model are shown in the
Supplementary Table. None of these polymorphisms was relat-
ed to CXCR4 or CCR5, or the MHC. Assuming an additive ge-
netic model and a variant frequency of 10%, the present sample
size provides >80% power to detect an odds ratio (OR) of 3 or
greater. Stand-alone meta-analyses across ancestral association
Table 1. Association of Patient and Clinical Characteristics With
Viral Coreceptor Usage As Determined by Phenotypic Assay
Coreceptor Usage
Adjusted
P ValuecX4-D/Ma R5 Onlyb
Number of patients 265 (44.5)d,e 330 (55.5)e
Age (median years) 37 37 .834
Gender
Male 210 (79.5) 263 (80.7) .695
Female 54 (20.5) 63 (19.3)
Race/Ethnicity
White 113 (42.8) 149 (46.0) .174
Black 103 (36.0) 101 (31.2)
Hispanic 44 (16.7) 73 (22.5)
Other/not reported 4 (1.5) 1 (0.3)
Baseline CD4+ T Cell
Count (median
cells/mm3)
154 261 <.001
Baseline VL (median
log10 copies/mL)
4.91 4.76 .993
CCR5 genotype
Δ32 heterozygous 31 (11.7) 27 (8.3) .058
Wild-type 233 (88.3) 299 (91.7)
Abbreviations: D/M, dual- or mixed-tropic virus populations; GWAS, genome-
wide association studies; VL, viral load.
a X4-D/M, viral population that uses either CXCR4 or both CXCR4 or CCR5 for
entry.
b R5, viral population that uses only CCR5 for entry.
c Adjusted P value from logistic regression models including all variables listed.
d Number and percent within coreceptor usage group.
eN = 593 included in GWAS analyses; 1 X4-D/M and 6 R5 patients with missing
clinical information excluded in regression modeling; 2 patients with missing
data included in regression analysis were excluded from the GWAS.
Table 2. List of SNPs Included in the GWAS Previously Associated With HIV-1 Disease Progression or Presence of X4-D/M Virus
Determined by Phenotypic Assay
OR (P value) for Association Analysis by Ancestry
SNPa Gene Marker Prior Reported Effect
European
(n = 266)
African American
(n = 209)
Hispanic
(n = 118)
Meta-Analysisa
(n = 593)
rs333 CCR5 Δ32 Decreased susceptibility [22] 1.45 (0.252) 4.03 (0.213) 1.9 (0.548) 1.59 (0.120)
rs1799987 CCR5 P1 Fast progression [20] 0.92 (0.677) 0.79 (0.309) 0.76 (0.375) 0.84 (0.205)
rs1800023 CCR5 A676G Slow progression [19] 1.04 (0.845) 1.00 (1.000) 0.66 (0.224) 0.94 (0.674)
rs1800024 CCR5 C927T Slow progression [19] 0.99 (0.976) 1.15 (0.575) 0.82 (0.581) 1.02 (0.908)
rs2734648 CCR5 G280T Slow progression [19] 1.13 (0.530) 0.84 (0.440) 0.81 (0.510) 0.96 (0.758)
rs1799988 CCR5 T627C Slow progression [19] 1.05 (0.795) 0.84 (0.384) 0.67 (0.183) 0.89 (0.353)
rs1799864 CCR2 V64I Slow progression [7] 0.97 (0.945) 1.03 (0.897) 0.84 (0.624) 0.97 (0.852)
rs1801157 SDF1 G801A
(3′A)
Fast progression (previously
associated with X4 virus) [18]
1.17 (0.506) 0.58 (0.241) 0.81 (0.642) 0.97 (0.888)
Abbreviations: D/M, dual- or mixed-tropic virus populations; GWAS, genome-wide association studies; HIV, human immunodeficiency virus; OR, odds ratio; SDF1,
stromal cell-derived factor 1, a CXCR4 ligand; SNP, single-nucleotide polymorphism.
a Association data combined across groups using inverse-variance weighted meta-analysis.
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data for HLA class 1 alleles and viral coreceptor usage adjusted
or not adjusted for baseline CD4+ T-cell count were performed.
The association between phenotypic coreceptor usage and sev-
eral HLA type 1 alleles had P values <.05, but none met the
Table 3. List of SNPs Included in the GWAS Previously Associated With HIV-1 Disease Progression or Presence of X4-D/M Virus
Determined by Phenotypic Assay in CD4+ T Cell-Adjusted Modelsa
OR (P value) for Association Analysis by Ancestry
SNPa Gene Marker Prior Reported Effect
European
(n = 266)
African American
(n = 209)
Hispanic
(n = 118)
Meta-Analysisa
(n = 593)
rs333 CCR5 Δ32 Decreased susceptibility [22] 1.56 (0.175) 5.01 (0.159) 1.63 (0.645) 1.70 (0.080)
rs1799987 CCR5 P1 Fast progression [20] 0.93 (0.716) 0.82 (0.408) 0.79 (0.439) 0.87 (0.287)
rs1800023 CCR5 A676G Slow progression [19] 1.03 (0.877) 0.92 (0.803) 0.70 (0.312) 0.92 (0.638)
rs1800024 CCR5 C927T Slow progression [19] 0.96 (0.918) 1.06 (0.827) 0.87 (0.701) 0.98 (0.929)
rs2734648 CCR5 G280T Slow progression [19] 1.14 (0.516) 0.80 (0.323) 0.90 (0.744) 0.96 (0.783)
rs1799988 CCR5 T627C Slow progression [19] 1.06 (0.757) 0.90 (0.609) 0.66 (0.183) 0.92 (0.505)
rs1799864 CCR2 V64I Slow progression [7] 0.93 (0.851) 0.87 (0.627) 0.88 (0.736) 0.89 (0.546)
rs1801157 SDF1 G801A
(3′A)
Fast progression (previously
associated with X4 virus) [18]
1.06 (0.705) 0.71 (0.494) 0.87 (0.770) 0.98 (0.930)
Abbreviations: D/M, dual- or mixed-tropic virus populations; GWAS, genome-wide association studies; HIV, human immunodeficiency virus; OR, odds ratio; SDF1,
stromal cell-derived factor 1, a CXCR4 ligand; SNP, single-nucleotide polymorphism.
a Model adjusted for baseline absolute CD4+ T cell counts.
b Association data combined across groups using inverse-variance weighted meta-analysis.
Figure 1. Manhattan plots of inverse log10 P values of association data from unadjusted models for each ancestral group (A–C), and combined across
ancestry (D) by inverse-variance weighted meta-analyses. No single-nucleotide polymorphisms were signiﬁcantly associated with coreceptor usage phe-
notype at the genome-wide signiﬁcance level (represented by the dashed lines) in any model. The genes encoding CXCR4, CCR5, and the major histocom-
patibility complex are located on chromosomes 2, 3, and 6, respectively.
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genome-wide threshold of signiﬁcance: A*30:01 (OR, 0.40;
P = .024), B*57:01 (OR, 4.41; P = .014). In addition, the associ-
ation between phenotypic coreceptor usage and several HLA
type 1 alleles had P values <.05 in the CD4+ T cell adjusted
model: A*30:01 (OR, 0.36; P = .017), A*33:01 (OR, 3.71;
P = 0.032), B*57:01 (OR, 5.25; P = .007), and C*17:01 (OR,
0.39; P = .05).
Association analyses between genotypically predicted viral cor-
eceptor usage and clinical factors and SNPs were also performed
on 612 samples. As with phenotypic coreceptor usage, no signiﬁ-
cant associations between SNPs and the presence of X4-D/M
virus were identiﬁed at the genome-wide level, but there was a
signiﬁcant association between X4-D/M and the presence of a
CCR5 Δ32 allele (P = .006) in non-GWAS regression analysis.
Compared with phenotypic methods, Geno2Pheno was 95.3%
speciﬁc but only 31.6% sensitive for detecting X4-D/M virus.
DISCUSSION
A genome-wide association analysis found no signiﬁcant asso-
ciation between any common human genetic variants and the
presence of X4-D/M virus in a large cohort of patients initiating
ﬁrst-line ART in ACTG protocol A5095. Although the sample
size had limited power to deﬁnitively exclude genetic associa-
tions, our ﬁndings suggest that host genetic factors, including
those that inﬂuence HIV-1 coreceptor expression, are either
rare or have only modest effects in determining HIV-1 corecep-
tor usage. The presence of the HLA B*57:01 was associated with
the presence X4-D/M phenotype in both the CD4+ T cell ad-
justed and unadjusted models but failed to reach statistical sig-
niﬁcance at the genome-wide level. It is interesting to note that
there is a known correlation between B*57:01 and slower disease
progression [34, 35], despite the fact that in this study patients
with this allele were more likely to have CXCR4-using virus.
A longitudinal study of HIV-1 evolution in 9 men with pro-
gressive HIV disease before ART showed that coreceptor usage
followed a predictable course, with X4-D/M viral variants
emerging in all patients during early to intermediate stages of
HIV-1 disease [36]. In larger cohorts, the timing of X4-D/M
emergence varies between individuals and R5 viruses have
been isolated from patients with advanced disease or AIDS
[1–7]. We identiﬁed an independent association between
lower baseline CD4+ T-cell counts and presence of X4-D/M
virus, consistent with the ﬁndings of previous studies [37, 38].
However, several previous studies are either cross-sectional or
determined coreceptor usage only at baseline. Host factors
not directly linked to genetic polymorphisms, such as changes
in the availability of HIV-1 target cells expressing different
amounts of CCR5 and CXCR4, may play an important role in
the evolution of viral coreceptor usage [14]. Cells with high lev-
els of CCR5 expression are reduced early in infection [39], driv-
ing virus to evolve an enhanced ability to enter cells expressing
low levels of CCR5 [40, 41]. CXCR4-using viruses may emerge
once the virus is unable to increase any further its capacity to
enter cells expressing low levels of CCR5.
We identiﬁed a marginal correlation between the presence of
X4-D/M virus and the presence of at least 1 copy of the CCR5
Δ32 mutation. A signiﬁcantly higher proportion of X4-D/M
virus in patients with decreased expression of functional
CCR5 has been observed in a prior study, and these data sup-
port the hypothesis that target cell selection guides the evolution
of HIV-1 env and coreceptor usage [17, 37]. Gene editing of
CCR5 in autologous CD4+ T cells conferred a selective advan-
tage for the genetically modiﬁed T cells when ART was inter-
rupted; the longest time to virologic rebound was observed in
a patient heterozygous for the CCR5 Δ32 mutation [12].
Whether this approach will select for emergence of X4-D/M
virus over time will require careful monitoring.
In the current analysis, the presence of X4-D/M virus was not
signiﬁcantly associated with the SDF1-3′A SNP in the genome-
wide analysis or in a stand-alone analysis. Stromal cell-derived
factor 1 is a CXCR4 ligand and endogenous inhibitor of CXCR4
and viral entry [42]. Presence of the SDF1-3′A polymorphism
was associated in a smaller study with faster disease progression
and with the presence of X4 virus [18]. Previous studies have
suggested that interleukin (IL)-7, which increases the density of
CXCR4 expression on the surface of CD4+ T cells surface, may be
associated with the emergence of X4 virus [43]. Likewise, homo-
zygosity of the IL-4 promoter region polymorphism 589T has
been correlated with increased rates of X4 virus conversion [43,
44]. Single-nucleotide polymorphisms in these IL genes were not
included in our analysis, but our failure to ﬁnd signiﬁcant asso-
ciations between coreceptor usage and the SDF1-3′A polymor-
phism highlights the importance of using large cohorts to
explore associations of host genetic factors on viral evolution.
Although this study included 593 patients with phenotypic
data on coreceptor usage, a limitation of this study was the rel-
atively limited power to detect associations in the genome-wide
context. Moreover, this study does not address the role of rare
sequence variants or copy number polymorphisms. Although a
number of low frequency variants could be imputed that may be
related to HIV-1 coreceptor usage [45], we were unable to detect
effects of variants <1% at genome-wide signiﬁcance in this
study due to the limited sample size.
Approximately 45% of pseudoviruses were X4-D/M by our
phenotypic assay, which is higher than the 18% X4-D/M prev-
alence by commercial phenotyping from a previous study of
coreceptor usage in treatment-naive individuals with baseline
CD4 counts and viral loads similar to those in the A5095 trial
[37]. The reason for this difference is not known but may reﬂect
differences in assay sensitivity. Dual-mixed HIV type 1 isolates
have varied considerably in their utilization of CCR5 and
CXCR4 coreceptors, with some isolates using low-levels of
CXCR4 [46]. Our assay may detect relatively low levels of
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CXCR4 usage. To minimize overcalling X4-D/M phenotype, the
mean luciferase relative luciferase units (RLUs) from pseudoviral
entry into cells expressing CXCR4 had to be signiﬁcantly higher
than the background RLU on the same cells from envelope-delet-
ed pseudoviral controls by t test, and RLUs had to decrease by at
least 50% in the presence of a small-molecule CXCR4 antagonist
[32]. The assay was designed and optimized for the categorical
determination of coreceptor-usage results, and it was not possible
to directly compare the strength of coreceptor usage on the assay
cell lines with the genomic data.
Despite these limitations, our ﬁndings suggest that host genetic
factors, including those that inﬂuence coreceptor expression or
the immune pressures leading to viral envelope diversity, are ei-
ther rare or of modest effect in determining HIV-1 coreceptor
usage. Pooled analyses of larger patient cohorts with available ge-
nome-wide SNP data and measured coreceptor usage are needed
to increase study power and to better understand the interplay
between host genetics and viral coreceptor usage.
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